Skip to content

VISTAGEN THERAPEUTICS, INC.: 10-Q filed 2016-02-16

What VISTAGEN THERAPEUTICS, INC. reported in its quarterly report filed 2016-02-16 (fiscal Q3 2016): 29 published measures, 80 facts as tagged in accession 0001415889-16-004781.

This filing

Form
10-Q (quarterly report)
Filed
2016-02-16
Fiscal period
fiscal Q3 2016
Accession
0001415889-16-004781 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VISTAGEN THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-12-312,012,200USD
At 2015-03-31269,700USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-12-313,610,500USD
At 2015-03-3120,812,500USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-12-31-1,598,300USD
At 2015-03-31-20,542,800USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-12-311,158,400USD
At 2015-03-3170,000USD
At 2014-12-3113,200USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-2,146,600USD92
2015-04-01 to 2015-12-31-38,718,800USD275
2014-10-01 to 2014-12-31-1,090,300USD92
2014-04-01 to 2014-12-31-7,664,500USD275

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2015-04-01 to 2015-12-31-3,498,900USD275
2014-04-01 to 2014-12-31-1,874,400USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2015-04-01 to 2015-12-314,591,900USD275
2014-04-01 to 2014-12-311,887,600USD275

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2015-04-01 to 2015-12-31-4,600USD275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-12-31-123,241,500USD
At 2015-03-31-84,522,700USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2015-10-01 to 2015-12-311,765,641shares92
2015-04-01 to 2015-12-311,650,160shares275
2014-10-01 to 2014-12-311,302,300shares92
2014-04-01 to 2014-12-311,270,495shares275

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2015-10-01 to 2015-12-311,765,641shares92
2015-04-01 to 2015-12-311,650,160shares275
2014-10-01 to 2014-12-311,302,300shares92
2014-04-01 to 2014-12-311,288,674shares275

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-1.95USD/shares92
2015-04-01 to 2015-12-31-25.45USD/shares275
2014-10-01 to 2014-12-31-0.84USD/shares92
2014-04-01 to 2014-12-31-6.03USD/shares275

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-1.95USD/shares92
2015-04-01 to 2015-12-31-25.45USD/shares275
2014-10-01 to 2014-12-31-1.08USD/shares92
2014-04-01 to 2014-12-31-6.14USD/shares275

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2015-04-01 to 2015-12-312,300USD275
2014-04-01 to 2014-12-312,400USD275

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2015-12-3178,600USD
At 2015-03-31117,100USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-10-01 to 2015-12-3198,400USD92
2015-04-01 to 2015-12-313,868,300USD275
2014-10-01 to 2014-12-31155,600USD92
2014-04-01 to 2014-12-31564,000USD275

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-2,141,800USD92
2015-04-01 to 2015-12-31-9,349,500USD275
2014-10-01 to 2014-12-31-1,116,700USD92
2014-04-01 to 2014-12-31-3,501,200USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-12-311,886,700USD
At 2015-03-31105,700USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2015-10-01 to 2015-12-312,500USD92
2015-04-01 to 2015-12-31769,800USD275
2014-10-01 to 2014-12-31792,400USD92
2014-04-01 to 2014-12-312,182,900USD275

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-12-312,101,600USD
At 2015-03-3117,388,100USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2015-12-311,097,600USD
At 2015-03-312,251,100USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-10-01 to 2015-12-312,141,800USD92
2015-04-01 to 2015-12-319,349,500USD275
2014-10-01 to 2014-12-311,116,700USD92
2014-04-01 to 2014-12-313,501,200USD275

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2015-12-31125,605,200USD
At 2015-03-3167,945,800USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2015-12-3146,900USD
At 2015-03-3146,900USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2015-12-31929,100USD
At 2015-03-311,206,500USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2015-12-31728,300USD
At 2015-03-3135,700USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-3,446,600USD92
2015-04-01 to 2015-12-31-41,989,900USD275
2014-10-01 to 2014-12-31-1,090,300USD92
2014-04-01 to 2014-12-31-7,664,500USD275

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-10-01 to 2015-12-311,335,500USD92
2015-04-01 to 2015-12-316,514,500USD275
2014-10-01 to 2014-12-31671,300USD92
2014-04-01 to 2014-12-312,024,600USD275

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2015-04-01 to 2015-12-31280,000USD275
2014-04-01 to 2014-12-312,128,200USD275

Inspect the source

Entity
VISTAGEN THERAPEUTICS, INC. / CIK 0001411685
Captured
2026-09-20T08:01:56.841Z
SEC response SHA-256
1d0d09c7b53b173e35f99fba8d3201ca751174b9bb70167acdba04307bebca91

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001411685.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))